• 1. School of Health Management, Southern Medical University, Guangzhou 510080, P. R. China;
  • 2. Health Management Center, Nanfang Hospital, Southern Medical University, Guangzhou 510080, P. R. China;
ZHOU Guangqing, Email: 13318898668@189.cn
Export PDF Favorites Scan Get Citation

Objective To analyze the variation trend of high low density lipoprotein cholesterol (LDL-C) attribution disease burden in China from 1990 to 2019. Methods The burden of disease indicators from Global Burden of Disease 2019 (GBD 2019), such as death attributable to high LDL-C, disability-adjusted life years (DALYs), years of life lost (YLLs), and years lost to disability (YLDs) were extracted. The age was standardized using GBD 2019 global standard population, and the trend of rates with the annual percentage change (APC) was analyzed. Results From 1990 to 2019, the disease burden of high LDL-C increased with age in China. The mortality rate, DALYs rate and YLLs rate of males were higher than those of females, while the YLDs rate of males was lower than that of females. Joinpoint regression results showed that from 1990 to 2019, the high LDL-C attribution mortality rate (APC=3.4%, P<0.05), DALYs rate (APC=2.4%, P<0.05), YLLs rate (APC=2.4%, P<0.05), YLDs rate (APC = 2.9%, P<0.05), the standardized mortality rate (APC=0.8%, P<0.05) and the standardized YLDs rate (APC=0.7%, P<0.05) all increased in China. Regarding age, the mortality rate, DALYs rate and YLLs rate increased in the age group over 70 years old, while the YLDs rate increased significantly in the age group over 45 years old. Conclusion From 1990 to 2019, the burden of disease attributable to high LDL-C in China has become increasingly heavy, and the burden varies according to gender and age.

Citation: YUAN Kongjun, ZHAO Chuangyi, YANG Yuan, YAN Danhong, ZHOU Guangqing. Burden trend analysis of disease attributable to high low density lipoprotein cholesterol in Chinese population from 1990 to 2019. Chinese Journal of Evidence-Based Medicine, 2022, 22(4): 444-449. doi: 10.7507/1672-2531.202112052 Copy

  • Previous Article

    Impact of ACEI/ARB on clinical outcomes in Chinese patients with COVID-19: a meta-analysis
  • Next Article

    Bibliometric analysis of health technology assessment